MedTrace Logo

An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol

NCT04788290 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3907

Last updated 2021-03-09

No results posted yet for this study

Summary

This study examines quality of life and patient satisfaction in postmenopausal women receiving raloxifene to prevent/treat osteoporosis, and vitamin D to reduce risk of fracture using clinical practice data. The purpose of this study is to observe quality of life(QOL), medication compliance and patient satisfaction who got combination therapy with raloxifene/cholecalciferol (raloxifene 60mg + cholecalciferol 800 IU, Rabone D®, Hanmi Pharma, South Korea) for 6 months.

Conditions

Interventions

OTHER

Observational

Rabone D®, Once daily administered per the locally approved product information

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Mi-Jeung KIM · Hanmi Pharmaceutical Company Limited

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2020-07-13
Completion
2020-07-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788290 on ClinicalTrials.gov